Stocks Health care APVO
NASDAQ · Health careAptevo Therapeutics Inc. (APVO)
It posted a net loss of $26.4M. At June 30, 2026 it held $9.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
What Aptevo Therapeutics Inc. does
Aptevo Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker APVO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$26M | -$87.27 | n/a |
| 2024 | n/a | -$24.1M | -$31,460.23 | n/a |
| 2023 | n/a | -$17.4M | -$834,149.74 | n/a |
| 2022 | $3.1M | $8M | $922,264.15 | -$21.1M |
| 2021 | $12.3M | -$28.5M | -$3,565,696.44 | -$22.4M |
| 2020 | $4.3M | -$17.8M | -$3,072,255.75 | -$29.4M |
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Aptevo Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 24, 2026Other event 8-K
- September 23, 2026
- September 3, 2026
- September 3, 2026Other event 8-K
- August 31, 2026Proxy statement DEF 14A
- August 21, 2026Preliminary proxy statement PRE 14A
- August 21, 2026IPO registration S-1
- August 21, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running Aptevo Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 13 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 6, 2026 | Niederhuber JohnDirector | Exercised options | 400 | - |
| August 6, 2026 | Kunz Barbara LopezDirector | Exercised options | 400 | - |
| August 6, 2026 | Abdun-Nabi DanielDirector | Exercised options | 400 | - |
| August 6, 2026 | White Marvin LExecutive Chair, Director | Exercised options | 1,666 | - |
| August 6, 2026 | White Marvin LExecutive Chair, Director | Shares withheld for tax | 406 | $1.7K |
| August 6, 2026 | Grant Grady IIIDirector | Exercised options | 400 | - |
| August 6, 2026 | Huebner DirkSVP, CMO | Exercised options | 638 | - |
| August 6, 2026 | Huebner DirkSVP, CMO | Shares withheld for tax | 156 | $634.9 |
| August 6, 2026 | Kwon SoYoungSVP, GC, BD & Corp Affairs | Exercised options | 638 | - |
| August 6, 2026 | Taylor DaphneSVP, CFO | Exercised options | 638 | - |
| August 6, 2026 | Lamothe Jeffrey G.President and CEO, Director | Exercised options | 961 | - |
| August 6, 2026 | Harsanyi ZsoltDirector | Exercised options | 400 | - |
| July 17, 2026 | White Marvin LExecutive Chair, Director | Exercised options | 1 | - |
Who owns APVO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Niowave, Inc.13G, passive | 12.2% | June 22, 2026 |
| CVI Investments, Inc.13G, passive with 1 related filers | 6.3% | August 14, 2026 |
Largest institutional holders
Insiders
10 insiders reported holding 6,730 shares in total, about $12.7K at the last price.
| Holder | Shares |
|---|---|
| White Marvin LExecutive Chair, Director | 1,261 |
| Grant Grady IIIDirector | 1,150 |
| Lamothe Jeffrey G.President and CEO, Director | 961 |
| Kwon SoYoungSVP, GC, BD & Corp Affairs | 638 |
| Taylor DaphneSVP, CFO | 638 |
| Huebner DirkSVP, CMO | 482 |
| Niederhuber JohnDirector | 400 |
| Abdun-Nabi DanielDirector | 400 |
| Kunz Barbara LopezDirector | 400 |
| Harsanyi ZsoltDirector | 400 |
Questions about APVO
What does Aptevo Therapeutics Inc. do?
Aptevo Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker APVO.
Is Aptevo Therapeutics Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $26.4M.
When did Aptevo Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the employee stock plan registration from September 25, 2026.
Similar companies
Compare APVO with
Follow APVO
Get an email when Aptevo Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow APVO: get an email when it filesWhere the numbers come from
Financial figures are the values Aptevo Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.